SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 213.35

Change

+4.55 (+2.18)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-16 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.21 (-0.75%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.29 (-0.57%)

USD 114.13B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.26 (-0.21%)

USD 106.46B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.30 (-0.52%)

USD 100.12B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.09 (-0.55%)

USD 63.18B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.87 (+1.73%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.15 (-0.06%)

USD 51.11B
XJSE:F Xtrackers II - Japan Governmen..

+0.07 (+0.87%)

USD 43.12B
0ZC:F Zscaler Inc

+5.56 (+3.12%)

USD 37.92B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.16% 32% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.16% 31% F 41% F
Trailing 12 Months  
Capital Gain 3.97% 34% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.97% 30% F 41% F
Trailing 5 Years  
Capital Gain 29.68% 60% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.68% 59% D- 46% F
Average Annual (5 Year Horizon)  
Capital Gain 9.21% 66% D+ 64% D
Dividend Return 9.21% 64% D 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.25% 74% C 93% A
Risk Adjusted Return 111.62% 97% N/A 97% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike